Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878482 | 0.88 | PPARD (0.57) | KEAP1NFE2L2MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL28559146 | 0.87 | MTNR1A (0.61) | KEAP1NFE2L2MTNR1AMTNR1BPPARG | |
| SCHEMBL19630730 | 0.83 | MTNR1A (0.57) | KEAP1NFE2L2MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL6151456 | 0.81 | MTNR1A (0.60) | KEAP1NFE2L2MTNR1AMTNR1BKDM4E | |
| SCHEMBL1520186 | 0.80 | KEAP1 (0.68) | KEAP1NFE2L2MTNR1AMTNR1BKDM4E | |
| SCHEMBL17785108 | 0.79 | MTNR1A (0.65) | MTNR1AMTNR1BKDM4E | |
| SCHEMBL8178169 | 0.79 | PLA2G2A (0.51) | KEAP1NFE2L2MTNR1AMTNR1BAKR1C2 | |
| SCHEMBL8171657 | 0.79 | KEAP1 (0.57) | KEAP1NFE2L2MTNR1AMTNR1BKDM4E | |
| SCHEMBL7340610 | 0.78 | MTNR1A (0.57) | MTNR1AMTNR1BHSD17B10KDM4E | |
| SCHEMBL8435916 | 0.78 | KEAP1 (0.64) | KEAP1NFE2L2MTNR1AMTNR1BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-5612368-A | SKIN DISORDERS, MELATONINERGIC SYSTEMS, ANTIARRHYTHMIA AGENTS OR ANTIISCHEMIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | KEAP1 1961/4885NFE2L2 3636/4885MTNR1A 233/4885 |
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | KEAP1 3982/4885NFE2L2 1360/4885MTNR1A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.